OTS - Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
2021. October 12. 10:30
Freiburg, Germany, 12 October, 2021 (APA/OTS) - Eleva, a
manufacturer of superior biologics, is entering clinical phases
with its own drug candidates, such as immune-regulating factor H,
as well as in collaboration with pharmaceutical partners. Its
moss-based platform is ideally suited to produce
difficult-to-express but therapeutically promising drug candidates.
Its recently expanded production capacity enables Eleva to
conduct clinical studies of its drug candidates. Among the first
ones is factor H which will be developed through phase II. Up to
2,500 l will be produced in state-of-the-art single-use reactors at
a GMP site.
Eleva's moss-based platform offers unique advantages for
recombinant protein development,
such as:
- Moss glycostructure naturally lacks core ?-1,6 fucose - a
known allergen - while any other glycans can be "humanized". This
leads to excellent organ uptake.
- Being a plant, it will not be contaminated with animal
pathogens, which eliminates the need for antibiotics.
- The moss production system, haploid by nature, is based on
an intact organism, not on cell cultures. This guarantees
exceptionally stable modifications.
Eleva is leveraging those advantages to produce complex
proteins for future therapies, such as 2nd generation oncological
therapeutics, or virus-like-particles (VLP) for vaccine development.
Ralf Smit, CBO of Eleva: "With production scaling up, we can
now offer to develop difficult-to-express therapeutic proteins in
collaboration with partners in the pharmaceutical industry. We look
forward to our moss platform unlocking the very promising potential
of complex candidates for the benefit of patients."
About Eleva
Based in Freiburg, Germany, Eleva develops novel biological
therapies with its pharmaceutical partners. The privately-held
company leverages its unique moss-based production platform to
produce supreme biologics like antibodies, replacement enzymes, or
fusion toxins. Eleva has successfully developed drug candidates
into clinical phases.
Press contact
eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 990
www.elevabiologics.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.